Shifting paradigms and bridging gaps

The future is already here – it’s just not evenly distributed.

William Gibson

In 1961, a laboratory accident led Neil Bartlett and his graduate student Derek Lohman to discover the first noble-gas compound. This discovery disproved a half-century old theory about noble gases; and created a whole new future of new materials.

In 1963, Bartlett survived a fatal explosion in his lab to live one-eyed until 2008, when he died from an aortic aneurysm. Albert Einstein, who disproved Newton’s two-century old theory of gravity died from the same condition in 1955.

Vascular (cardiovascular and cerebrovascular) disease kills over 17 million people a year and is the world’s first cause of death. The term includes numerous conditions that all share more or less similar features. These features mainly lead to functional loss in part of the arterial tree, leading to varying complications.

Our arteries are lined with a single layer of endothelial cells (ECs) that regulate the intertwining functions of vascular tissue and blood flow. Each of these cells senses the flow through a network of mechano-sensors acting on its cytoskeleton. This mechano-sensory behavior is believed to contribute to biologic functions of ECs and the general physiologic condition of vascular tissue. In all conditions of vascular disease, affected arteries demonstrate degrees of endothelial dysfunction associated with non-physiologic flow of different, still uncharacterized, regimes.

The relationship between ECs and blood flow dynamics is a central paradigm in all vascular disease models, from atherosclerosis to aneurysm. Over the past four decades, significant progress has been made towards completing this paradigm. Technology, as usual, did not wait. Researchers have developed a multitude of successful devices to control blood flow in a way to allow diseased endothelial cells to heal and vascular tissue to recover. However, these achievements cannot slow the globally increasing rate of vascular disease and associated morbidity.

Research findings from different focus groups around the world, in the past decade, prophesize a paradigm-shift in vascular medicine. The way researchers understood the dynamics of blood flow has radically changed. Also, research into ECs mechanosensory and underlying epigenetics and metabolomics revealed new dimensions that promise a hopeful future for patients with vascular disease.

EVBio members are pioneering researchers, from all disciplines, who actively contribute towards the ongoing paradigm shift in vascular medicine. Our global network is driven by biologists, engineers, surgeons and physiologists who are united to accomplish one mission: to create transdisciplinary solutions for a multidisciplinary problem.

EVBio promotes and supports disruptive research in all fields of vascular biology and medicine. We connect the latest scientific achievements through innovative scenarios to empower better diagnostics and therapeutics. We work with all stakeholders in the vascular medicine sector to discover future-shaping opportunities.